drugset / Trial / NCT03579940

A Study of Lasmiditan in Healthy Japanese and Caucasian Participants

NCT03579940

Phase 1 Completed 27 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of lasmiditan in healthy Japanese and Caucasian participants. The study will also investigate how much lasmiditan gets into the bloodstream and how long it takes the body to get rid of lasmiditan when given to Japanese and Caucasians. The study will last up to 47 days for each participant.

Timeline

Start
2018-06-27
Primary completion
2018-08-09
Completion
2018-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lasmiditan Small molecule 50 mg Oral
Subject Lasmiditan Small molecule 100 mg Oral
Subject Lasmiditan Small molecule 200 mg Oral
Subject Lasmiditan Small molecule 400 mg Oral

Indications

No indication recorded.